Weight problems and Alzheimer’s medicine pack one-two punch to elevate Eli Lilly
Investor optimism for Eli Lilly 's diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should…
Jim Faile has done it all in his 27 year as an Author, Editor, Writer, Copywriter, Blogger, and Mentor. You name a newsroom beat and Jim has covered it with the best of them. He also loves his dogs, traveling, Rays baseball, and dreaming up his next writing project.
Recover your password.
A password will be e-mailed to you.